Clinical trials: Cord Blood
Sickle Cell Disease, Beta Thalassemia
Stem Cell Transplant in Sickle Cell Disease and Thalassemia
The primary purpose of this study is to see if giving lower doses of chemotherapy (moderately ablative) will result in successful bone marrow replacement without as severe side-effects but with permanent control of the disease.
- Trial name
- NCT00408447
- Testing
- Busulfan, Fludarabine, Alemtuzumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Columbia University
Immune Effector Cell Associated Hematotoxicity
Safety and Efficacy of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in the Treatment of Long-Term Cytopenia After CAR-T Therapy
This study is a single arm, open label, exploratory clinical study aimed at evaluating the efficacy, and safety of allogeneic umbilical cord blood-derived mesenchymal stem cells in the treatment of long-term cytopenia after CAR-T…
- Trial name
- MSC-ICAHT (NCT07212335)
- Testing
- Mesenchymal Stem Cell Infusion
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Pediatric Cancer
Granulocyte Transfusions After Umbilical Cord Blood Transplant
Although most children with leukaemia are cured using drugs (chemotherapy) alone, for some children additional treatments are needed. Stem cell transplant can cure children where chemotherapy and other drugs have failed.
- Trial name
- NCT05425043
- Testing
- Granulocytes
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Manchester
Premature Ovarian Failure，
Stem Cell Therapy Combined Hormone Replacement Therapy in Patients With Premature Ovarian Failure
Premature ovarian failure (POF) refers the occurrence of amenorrhoea, elevated serum gonadotrophins and hypoestrogenism levels in female before the age of 40.
- Trial name
- NCT01742533
- Testing
- human umbilical cord mesenchymal stem cells, hUCMSCs and hCBMNCs, human cord blood mononuclear cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shenzhen Beike Bio-Technology Co., Ltd.
Autonomic Dysreflexia
Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)
This study will be investigating the effects of fesoterodine on autonomic dysreflexia (AD) in patients with spinal cord injuries (SCI).
- Trial name
- NCT02676154
- Testing
- Fesoterodine
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- University of British Columbia
Leukemia, Lymphoma
Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases
- Trial name
- NCT00055653
- Testing
- anti-thymocyte globulin, filgrastim, busulfan
- Where
- 25 sites in United States
- Sponsor
- Roswell Park Cancer Institute
Refractory/Recurrent Central Nervous System Lymphoma
Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma
This study is designed to evaluate the safety and efficacy of cord blood-derived CAR-NK019 in the treatment of refractory/relapsed central nervous system lymphoma.
- Trial name
- NCT06827782
- Testing
- anti-CD19 CAR-NK cells
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Single Umbilical Cord Blood Transplantation, Non-myeloablative Conditioning
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant
This study was designed to evaluate the safety and tolerability of HSC835 for clinical use as measured by the absence of graft failure at day 42 in excess of that currently observed with double umbilical cord blood (UCB)…
- Conditions
- Single Umbilical Cord Blood Transplantation, Non-myeloablative Conditioning, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- UCBT (NCT01930162)
- Testing
- HSC835
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Pilot Study of Unrelated Cord Blood Transplantation
The purpose of this study is to determine the safety and feasibility of unrelated double and single cord blood transplantation in patients with haematological malignancies using reduced-intensity or myeloablative conditioning…
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Leukemia, Lymphoblastic, Acute, Lymphoma, Non-Hodgkin
- Trial name
- NCT00916045
- Testing
- Thiotepa, Fludarabine, Intravenous busulphan
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- King's College Hospital NHS Trust
Traumatic Brain Injury
Allogeneic Umbilical Cord Blood Therapy for Chronic TBI
This open label trial is conducted to investigate the efficacy and safety of umbilical cord blood therapy for chronic traumatic brain injury patients.
- Trial name
- NCT01451528
- Testing
- Allogeneic Umbilical Cord Blood
- Where
- South Korea
- Sponsor
- Bundang CHA Hospital
Leukemia, Lymphoma
New York Blood Center National Cord Blood Program
Umbilical cord blood is used as a source of hematopoietic stem cells for bone marrow reconstitution in patients who would be potential candidates for a bone marrow transplant from an unrelated marrow donor.
- Conditions
- Leukemia, Lymphoma, Genetic Disease, Severe Aplastic Anemia
- Trial name
- NCT00212407
- Testing
- Umbilical Cord Blood Transplantation
- Where
- United States
- Volunteers
- 4,476 people
- Sponsor
- New York Blood Center
Aplastic Anaemia
Conditioning Regimen Containing Low-Dose ATG for the Treatment of AA Receiving sUCBT
To evaluate the safety and efficacy of Single Umbilical Cord blood transplantation (sUCBT) containing low dose ATG based conditioning regimen in the treatment of Aplastic Anemia (AA)
- Trial name
- NCT07885982
- Testing
- Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Anhui Provincial Hospital
Spinal Cord Injury
Lithium, Cord Blood Cells and the Combination in the Treatment of Acute & Sub-acute Spinal Cord Injury
The trial is to investigate the safety and efficacy of oral lithium, intraspinal umbilical cord blood mononuclear cell transplant, and the combination in the treatment of acute and subacute spinal cord injury
- Trial name
- NCT01471613
- Testing
- Conventional Treatment, Lithium Carbonate Tablet, Cord Blood Cell
- Where
- China
- Volunteers
- 16 people
- Sponsor
- China Spinal Cord Injury Network
Patients With Advanced Lymphoid Malignancies in the Absence of an HLA Identical or Mismatch Donor
Cord Blood Transplantation in Patients With Advanced Lymphoid Malignancies
Indication: Patients with advanced lymphoid malignancies in the absence of an HLA identical or mismatch donor. Objectives: Overall survival at one year. Efficacy >60%, rejection rate <20%.
- Trial name
- LYMPHCORD (NCT01966510)
- Testing
- Cord Blood Transplantation
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Intraosseous Infusion of Unrelated Cord Blood Grafts
In this trial the investigators seek to determine if injecting cord blood cells directly into the bone marrow (intraosseous injection), rather than infusing them intravenously, can improve engraftment.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00967525
- Testing
- cord blood infusion
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Health Status Unknown
Studying Umbilical Cord Blood From African-American Donors
RATIONALE: Studying umbilical cord blood in the laboratory and gathering information about current and previous pregnancies from African-American umbilical cord blood donors may help doctors learn more about the umbilical cord…
- Trial name
- NCT00717535
- Testing
- cryopreservation, questionnaire administration, study of socioeconomic and demographic variables
- Volunteers
- healthy volunteers welcome
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Cerebral Palsy
Treatment of Children With Cerebral Palsy With Autologous Umbilical Cord Blood, a Pilot Study
This study is a phase II, prospective, double blind, placebo-controlled study of the efficacy of autologous umbilical cord blood infusion.
- Trial name
- NCT04243408
- Testing
- Autologous umbilical cord blood transfusion
- Where
- Israel
- Volunteers
- 72 people
- Sponsor
- Sheba Medical Center
Severe Combined Immunodeficiency Disease
Multi-center Clinical Study of Cord Blood Stem Cell Transplantation for SCID
Severe combined immunodeficiency (SCID) is a rare disease caused by a group of genetic disorders that leads to early death from recurrent infections in affected children.The only curative therapy for SCID is allogeneic…
- Trial name
- NCT04172181
- Testing
- cord blood stem cell transplantation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Children's Hospital of Fudan University
Neurological Diseases, Stroke
Allogeneic Cord Blood for Neurological Diseases in Adults
This open label trial is conducted to investigate the efficacy and safety of allogeneic umbilical cord blood therapy for adult patients with neurological diseases.
- Conditions
- Neurological Diseases, Stroke, Spinal Cord Injuries
- Trial name
- NCT05515419
- Testing
- Allogeneic cord blood treatment
- Sponsor
- The Medical Pavilion Bahamas
Degenerative Osteoarthritis, Defect of Articular Cartilage
Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect
This is a long term follow-up study to investigate the safety and efficacy of CARTISTEM®, human umbilical cord blood-derived mesenchymal stem cells, in repair of cartilage injury or defects, compared with microfracture.
- Trial name
- NCT01626677
- Testing
- CARTISTEM, Microfracture
- Where
- 10 sites in South Korea
- Volunteers
- 103 people
- Sponsor
- Medipost Co Ltd.